{"prompt": "['Table 8', 'Objectives and Corresponding Enppoints', 'Objectives', 'Corresponding Endpoints', 'Primary Objective:', 'To evaluate the overall safety and', 'Incidence and severity of all adverse events,', 'tolerability of prophylactic', 'including thromboembolic events, microangiopathic', 'administration of emicizumab', 'hemolytic anemia or TMA (e.g. hemolytic uremic', 'syndrome), systemic hypersensitivity, anaphylaxis,', 'and anaphylactoid events', 'Changes in physical examination findings, vital', 'signs, and laboratory parameters', 'Secondary Objective:', 'To evaluate the efficacy of', 'To evaluate the efficacy of prophylactic', 'prophylactic administration of', 'administration of emicizumab on the basis of the', 'emicizumab', 'number of bleeds over time', 'To evaluate the HRQoL of patients according to', 'Haem-A-QoL (= 18 y) or Haemo-QoL-SF (ages', '12-17) scores over time', 'To evaluate the health status of patients according', 'to EQ-5D-5L scores over time', 'To assess patient preference for the emicizumab', 'regimen compared with the previous regimen used', 'Immunogenicity Objective:', 'To evaluate the immunogenicity of', 'To assess the incidence and clinical significance of', 'emicizumab', 'anti-emicizumab antibodies', 'PK Objective:', 'To obtain emicizumab PK data', 'To obtain PK data for emicizumab at defined', 'timepoints', 'EQ-5D-5L=EuroQoL Five-Dimension-Five Levels Questionnaire; Haem-A-QoL=Hemophilia Adult', 'Quality of Life Questionnaire; Haemo-QoL-SF=Hemophilia Quality of Life Short Form;', 'HRQoL=Health-Related Quality of Life; PK=pharmacokinetic; TMA=thrombotic microangiopathy', '3.', 'STUDY DESIGN', '3.1', 'DESCRIPTION OF THE STUDY', 'This single-arm, multicenter, open label Phase IIIb clinical study will enroll patients aged 12', 'years or older with congenital hemophilia A who have persistent inhibitors against FVIII at', 'enrollment. Approximately 200 patients with inhibitors will be enrolled globally. Patients will', 'receive prophylactic emicizumab at 3 mg/kg/week subcutaneously for 4 weeks, followed by', '1.5 mg/kg/week subcutaneously for the remainder of the 2-year treatment period (Figure 1).', 'Emicizumab - F. Hoffmann-La Roche Ltd', '101 / Protocol MO39129, Version 3']['Figure 1', 'Study Design', 'Patients with congenital', 'hemophilia A of any', 'Initial dose:', 'Maintenance dose:', 'severity who have', 'Emicizumab', 'Emicizumab', 'inhibitors against FVIII', '3 mg/kg/wk SC', '1.5 mg/kg/wk SC', '(n=200)', '4 weeks', '2 years', 'FVIII=Factor VIII; SC=subcutaneous', 'The primary objective of this study is to evaluate the overall safety and tolerability of', 'prophylactic administration of emicizumab in patients with congenital hemophilia A who have', 'persistent inhibitors against FVIII at enrollment. In order to achieve this objective, all adverse', 'events, including adverse events of special interest, will be captured on an ongoing basis, as', 'they occur during the study. Physical examinations, vital signs, and laboratory values will be', 'assessed as per the Schedule of Activities (Appendix 1', 'Schedule of Activities', ').', 'The secondary objective of this study is to evaluate the efficacy of prophylactic', 'administration of emicizumab. As part of this objective, the number of bleeds over time will', 'be recorded for all of the enrolled patients.', 'The final analysis will be conducted when all patients have completed 2 years of treatment', 'or have withdrawn, whichever occurs sooner. Patients, or their legally authorized', 'representative, will be asked to report bleed information on an electronic patient-reported', 'outcome (ePRO) device where possible, including site of bleed, type of bleed, time of each', 'individual bleed (day, start and stop time), and treatment for bleed. HRQoL will be assessed', 'and the EuroQoL Five-Dimension-Five Levels Questionnaire (EQ-5D-5L) will be completed', 'prior to the first emicizumab administration (Week 1), at the Month 3, 6, 12, and 18', 'assessments, and at study completion as outlined in the Schedule of Activities (Appendix 1', 'Schedule of Activities', '). Additional secondary endpoints include assessing patient preference for the emicizumab', 'regimen compared with the previous regimen using a questionnaire (EmiPref).', 'Immunogenicity will be monitored by incidence and clinical significance of antibodies to', 'emicizumab. In addition, PK data for emicizumab will be obtained at defined timepoints as', 'per the Schedule of Activities (Appendix 1', 'Schedule of Activities', ').', 'Drugs intended to control breakthrough bleeds (e.g. rFVII, FVIII, aPCC) or bleeds during surgeries', 'should be used at the lowest dose expected to achieve hemostasis. Given that circulating emicizumab', \"may increase the patient's coagulation potential, the doses required to achieve hemostasis may be\", 'lower than doses used prior to starting emicizumab. Investigators shall discuss at the start of the', 'Emicizumab - F. Hoffmann-La Roche Ltd', '102 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}